Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020		Dec. 31, 2019	Dec. 31, 2018
Consolidated Statements Of Operations [Abstract]
Revenue, net	$ 102,773	[1]	$ 113,493	$ 113,948
Cost of goods sold	76,598		82,507	77,717
Gross profit	26,175		30,986	36,231
Operating expenses:
Sales and marketing	6,671		11,498	11,467
General and administrative	15,007		13,933	11,718
Research and development	5,248		3,830	4,671
Restructuring charges	1,171
Other operating expenses	1,153
Impairment loss (Note 6 and 7)			3,765
Total operating expenses	29,250		33,026	27,856
Operating (loss) income	(3,075)		(2,040)	8,375
Interest income (expense), net	331		920	(314)
Other income (expense), net	316		(743)	(815)
(Loss) income from continuing operations before income taxes and discontinued operations	(2,428)		(1,863)	7,246
Income tax expense	61		201	484
(Loss) income from continuing operations before discontinued operations	(2,489)		(2,064)	6,762
Loss on disposal of discontinued operations (Note 4)			(1,116)
Loss from discontinued operations (Note 4)			(597)	(1,215)
Net (loss) income	(2,489)		(3,777)	5,547
Less: Income allocated to non-controlling interest	35
Net (loss) income attributable to Intricon shareholders	$ (2,524)		$ (3,777)	$ 5,547
Basic (loss) income per share attributable to Intricon shareholders:
Continuing operations	$ (0.28)		$ (0.23)	$ 0.89
Discontinued operations			(0.20)	(0.16)
Net (loss) income per share:	(0.28)		(0.43)	0.73
Diluted (loss) income per share attributable to Intricon shareholders:
Continuing operations	(0.28)		(0.23)	0.78
Discontinued operations			(0.20)	(0.14)
Net (loss) income per share:	$ (0.28)		$ (0.43)	$ 0.64
Average shares outstanding:
Basic	8,894		8,748	7,599
Diluted	8,894		8,748	8,630

[1] During the quarter ended March 31, 2020, we recorded a cumulative adjustment of $1.2 million to reduce revenue within our other medical market to correct an error related to prior periods as a result of our determination that a portion of our sales being recognized over time needed to be recognized at a point in time. The adjustment included a reduction of the related cost of goods sold of $0.8 million and related impacts to reduce the contract asset and an increase to inventory. The adjustment was not material to our Consolidated Financial Statements for any quarterly or annual period.